Cuijpers Pim, Turner Erick H, Koole Sander L, van Dijke Annemiek, Smit Filip
Department of Clinical Psychology, VU University Amsterdam, The Netherlands; EMGO Institute for Health and Care Research, VU University Medical Center Amsterdam, VU University Amsterdam, The Netherlands; Leuphana University, Lünebrug, Germany.
Depress Anxiety. 2014 May;31(5):374-8. doi: 10.1002/da.22249. Epub 2014 Feb 22.
Randomized trials can show whether a treatment effect is statistically significant and can describe the size of the effect. There are, however, no validated methods available for establishing the clinical relevance of these outcomes. Recently, it was proposed that a standardized mean difference (SMD) of 0.50 be used as cutoff for clinical relevance in the treatment of depression.
We explore what the effect size means and why the size of an effect has little bearing on its clinical relevance. We will also examine how the "minimally important difference," as seen from the patient perspective, may be helpful in deciding where the cutoff for clinical relevance should be placed for a given condition.
Effect sizes in itself cannot give an indication of the clinical relevance of an intervention because the outcome itself determines the clinical relevance and not only the size of the effects. The "minimal important difference" (MID) could be used as a starting point for pinpointing the cutoff for clinical relevance. A first, rough attempt to implement this approach for depression resulted in a tentative clinical relevance cutoff of SMD = 0.24. Using this cutoff, psychotherapy, pharmacotherapy, and combined treatment have effect sizes above this cutoff.
Statistical outcomes cannot be equated with clinical relevance. The "MID" may be used for pinpointing the cutoff for clinical relevance, but more work in this area is needed.
随机试验能够表明一种治疗效果在统计学上是否显著,并能描述该效果的大小。然而,目前尚无经过验证的方法可用于确定这些结果的临床相关性。最近,有人提议将标准化均数差值(SMD)为0.50用作抑郁症治疗中临床相关性的临界值。
我们探讨效应量意味着什么,以及为什么效应的大小与其临床相关性几乎没有关系。我们还将研究从患者角度来看的“最小重要差异”如何有助于确定给定病症临床相关性的临界值应设定在哪里。
效应量本身并不能表明一项干预措施的临床相关性,因为结果本身决定临床相关性,而不仅仅是效应的大小。“最小重要差异”(MID)可作为确定临床相关性临界值的起点。首次对抑郁症实施这种方法的粗略尝试得出了SMD = 0.24的暂定临床相关性临界值。使用这个临界值,心理治疗、药物治疗和联合治疗的效应量均高于此临界值。
统计学结果不能等同于临床相关性。“MID”可用于确定临床相关性的临界值,但该领域还需要更多研究。